| Code | CSB-RA011593MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ordesekimab, targeting interleukin-15 (IL-15), a pleiotropic cytokine that plays crucial roles in immune cell activation, proliferation, and survival. IL-15 signals through a heterotrimeric receptor complex and is essential for the development and maintenance of natural killer cells, CD8+ memory T cells, and other lymphocyte populations. Dysregulated IL-15 expression and signaling have been implicated in various autoimmune disorders, inflammatory conditions, and certain T-cell malignancies, including celiac disease, rheumatoid arthritis, and cutaneous T-cell lymphoma.
Ordesekimab, the reference antibody, is a therapeutic monoclonal antibody designed to neutralize IL-15 activity by blocking its interaction with the IL-15 receptor. This biosimilar provides researchers with a valuable tool for investigating IL-15-mediated immune responses, studying cytokine signaling pathways, and exploring potential therapeutic interventions in IL-15-associated diseases. It enables the examination of IL-15 biology in various experimental models and supports translational research efforts in immunology and oncology.
There are currently no reviews for this product.